Cell line · CVCL_3612
Papers54
1 to 20 of 54
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Hsa_Circ_0000615-Encoded 250-Amino Acid Polypeptide Suppresses Epithelial Ovarian Cancer Progression via Promoting HMGB1 Nuclear Accumulation. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERX-208 Induces Endoplasmic Reticulum Stress and Suppresses DNA Damage Repair to Enhance Chemotherapy Sensitivity. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Two-step PEG-based surface functionalization of gold nanoparticles enables specific SERS imaging of EGFR in an ovarian cancer cell model. | Mater Today Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Alpelisib enhances cisplatin mediated cytotoxicity in non-mutated, PIK3CA-dependent high-grade serous ovarian cancer. | J Ovarian Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Universal principles of cell population growth follow from local contact inhibition. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The USP19-DnaJC7 Axis Stabilizes p53 in Cisplatin-Treated Epithelial Ovarian Cancer. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. | Adv Biol (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. | Redox Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer. | Signal Transduct Target Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer. | Open Med (Wars) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SLFN11-mediated tRNA regulation induces cell death by disrupting proteostasis in response to DNA-damaging agents. | Nucleic Acids Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Molecular mechanisms of CAND2 in regulating SCF ubiquitin ligases. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 39829761 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. | Oncogene | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The PSI Domain of the MET Oncogene Encodes a Functional Disulfide Isomerase Essential for the Maturation of the Receptor Precursor. | Int J Mol Sci | 2022 | Its Methods give the RRID and name the line | PubMed | |
| A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. | Nat Commun | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3612/papers